Specifically, the addition of TKIs and anti-VEGF agents may enhance immune cell infiltration by normalizing tumor vasculature and reducing the accumulation of immunosuppressive cells (e.g., MDSCs and Tregs), thereby fostering a more immunosupportive tumor microenvironment. The gene discussed is VEGFA; the disease is neoplasm.